Literature DB >> 15583447

Ecarin chromogenic assay--a new method for quantitative determination of direct thrombin inhibitors like hirudin.

U Lange1, G Nowak, E Bucha.   

Abstract

A new sensitive and precise method for quantitative determination of direct thrombin inhibitors is described, the ecarin chromogenic assay (ECA). Ecarin is used as the specific prothrombin-activating principle. The cleavage of a chromogenic substrate by meizothrombin is inhibited in a concentration-dependent fashion by direct thrombin inhibitors. For the ECA, the linear measuring range is about 0.1-3.0 microg hirudin/ml plasma. Coefficients of variations between 2.3 and 4% over the whole concentration range were achieved. The ECA has proved to be more sensitive than the compared tests (ecarin clotting time and a thrombin-based chromogenic assay); a detection limit of 0.011 microg hirudin/ml and a quantitation limit of 0.032 microg hirudin/ml were calculated. The ECA is independent of the variations of the coagulation variables fibrinogen and prothrombin. Neither heparin nor oral anticoagulants interfere with the ECA. Copyright 2004 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15583447     DOI: 10.1159/000081506

Source DB:  PubMed          Journal:  Pathophysiol Haemost Thromb        ISSN: 1424-8832


  15 in total

Review 1.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 2.  Measuring the anticoagulant effects of target specific oral anticoagulants-reasons, methods and current limitations.

Authors:  Helen Mani; Alexander Kasper; Edelgard Lindhoff-Last
Journal:  J Thromb Thrombolysis       Date:  2013-08       Impact factor: 2.300

3.  Ecarin modified rotational thrombelastometry: a point-of-care applicable alternative to monitor the direct thrombin inhibitor argatroban.

Authors:  Eva Schaden; Andreas Schober; Stefan Hacker; Sibylle Kozek-Langenecker
Journal:  Wien Klin Wochenschr       Date:  2013-02-26       Impact factor: 1.704

Review 4.  Reversal Strategies for NOACs: State of Development, Possible Clinical Applications and Future Perspectives.

Authors:  Steen Husted; Freek W A Verheugt; Willemijn J Comuth
Journal:  Drug Saf       Date:  2016-01       Impact factor: 5.606

Review 5.  Direct thrombin inhibitors: pharmacology and application in intensive care medicine.

Authors:  Eva Schaden; Sibylle A Kozek-Langenecker
Journal:  Intensive Care Med       Date:  2010-04-28       Impact factor: 17.440

Review 6.  [Old and new anticoagulants. Antidotes and measures for acute hemorrhaging and urgent interventions].

Authors:  M Lancé; B Stessel; K Hamulyák; M A Marcus
Journal:  Anaesthesist       Date:  2010-01       Impact factor: 1.041

Review 7.  Laboratory Monitoring of Direct Oral Anticoagulants (DOACs).

Authors:  Claire Dunois
Journal:  Biomedicines       Date:  2021-04-21

Review 8.  Monitoring of hematological and hemostatic parameters in neurocritical care patients.

Authors:  Andrew M Naidech; Monisha A Kumar
Journal:  Neurocrit Care       Date:  2014-12       Impact factor: 3.210

9.  Reversible crystallization of argatroban after subcutaneous application in pigs.

Authors:  Mercedes Lopez; Goetz Nowak
Journal:  Thrombosis       Date:  2012-09-03

10.  Thrombin has biphasic effects on the nitric oxide-cGMP pathway in endothelial cells and contributes to experimental pulmonary hypertension.

Authors:  Katrin F Nickel; Volker Laux; Rolf Heumann; Georges von Degenfeld
Journal:  PLoS One       Date:  2013-06-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.